دورية أكاديمية
أعرض في EDS

Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.
المؤلفون: Tummers WS; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Farina-Sarasqueta A; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Boonstra MC; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Prevoo HA; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Sier CF; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Mieog JS; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Morreau J; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van Eijck CH; Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands., Kuppen PJ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., van de Velde CJ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Bonsing BA; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Swijnenburg RJ; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
المصدر: Oncotarget [Oncotarget] 2017 May 26; Vol. 8 (34), pp. 56816-56828. Date of Electronic Publication: 2017 May 26 (Print Publication: 2017).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مستخلص: Discrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP) or peritumoral inflammation is challenging, both at preoperative imaging and during surgery, but it is crucial for proper therapy selection. Tumor-specific molecular imaging aims to enhance this discrimination and to help select and stratify patients for resection. We evaluated various biomarkers for the specific identification of PDAC and associated lymph node metastases. Using immunohistochemistry (IHC), expression levels and patterns were investigated of integrin αvβ6, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), Cathepsin E (Cath E), epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-MET), thymocyte differentiation antigen 1 (Thy1), and urokinase-type plasminogen activator receptor (uPAR). In a first cohort, multiple types of pancreatic tissue were evaluated (n=62); normal pancreatic tissue (n=8), CP (n=7), PDAC (n=9), tumor associated lymph nodes (n=32), and PDAC after neoadjuvant radiochemotherapy (n=6). In a second cohort, tissues were investigated (n=55) with IHC and immunofluorescence (IF) for concordance of biomarker expression in all tissue types, obtained from an individual patient. Integrin αvβ6 and CEACAM5 showed significantly higher expression levels in PDAC versus normal pancreatic tissue (P=0.001 and P<0.001, respectively) and CP (P=0.003 and P<0.001, respectively). Avβ6 and CEACAM5 expression identified tumor-positive lymph nodes correctly in 84% and 68%, respectively, and in 100% of tumor-negative nodes for both biomarkers. In conclusion, αvβ6 and CEACAM5 are excellent biomarkers to differentiate PDAC from surrounding tissue and to identify lymph node metastases. Individually or combined, these biomarkers are promising targets for tumor-specific molecular imaging of PDAC.
Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
References: J Gastrointest Oncol. 2011 Sep;2(3):168-74. (PMID: 22811847)
Nat Rev Cancer. 2006 Dec;6(12):924-35. (PMID: 17109012)
Semin Cancer Biol. 1999 Apr;9(2):67-81. (PMID: 10202129)
Colorectal Dis. 2013 Sep;15(9):e503-11. (PMID: 23711333)
Am J Pathol. 2009 Jun;174(6):2246-53. (PMID: 19435784)
J Biomed Sci. 2014 Apr 29;21:35. (PMID: 24780003)
Arch Pathol Lab Med. 2009 Apr;133(4):633-42. (PMID: 19391665)
Clin Cancer Res. 2015 Nov 15;21(22):5015-20. (PMID: 26567360)
J Clin Pathol. 2014 Apr;67(4):295-300. (PMID: 24170210)
Ann Surg. 2015 Jan;261(1):12-7. (PMID: 25599322)
PLoS One. 2014 Dec 23;9(12):e115507. (PMID: 25536077)
Histopathology. 2004 Sep;45(3):226-36. (PMID: 15330800)
Ann Surg Oncol. 2015 Apr;22(4):1153-9. (PMID: 25358667)
Oncology. 2016;91(2):85-9. (PMID: 27260164)
Cancer Metastasis Rev. 2008 Dec;27(4):655-64. (PMID: 18523731)
Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647)
Ann Surg Oncol. 2014 Nov;21(12):3999-4006. (PMID: 24871781)
Technol Cancer Res Treat. 2013 Aug;12(4):311-21. (PMID: 23369156)
J Surg Oncol. 2015 Jul;112(1):2-8. (PMID: 26074273)
Arq Gastroenterol. 2009 Jan-Mar;46(1):26-31. (PMID: 19466306)
Nat Rev Clin Oncol. 2013 Sep;10(9):507-18. (PMID: 23881033)
Clin Cancer Res. 2012 Feb 1;18(3):839-49. (PMID: 22173551)
Dis Colon Rectum. 1989 May;32(5):389-97. (PMID: 2714130)
PLoS One. 2014 Nov 19;9(11):e113023. (PMID: 25409014)
Asian Pac J Cancer Prev. 2013;14(9):5133-9. (PMID: 24175789)
Gastroenterology. 2013 Oct;145(4):885-894.e3. (PMID: 23791701)
J Hepatobiliary Pancreat Surg. 2008;15(4):429-35. (PMID: 18670846)
Int J Cancer. 1973 May;11(3):681-7. (PMID: 4791225)
Surg Clin North Am. 2013 Jun;93(3):647-62. (PMID: 23632150)
Nat Med. 2015 Aug;21(8):955-61. (PMID: 26168295)
Anticancer Res. 2001 Jul-Aug;21(4B):3031-6. (PMID: 11712806)
Lancet. 2011 Aug 13;378(9791):607-20. (PMID: 21620466)
Ann Surg Oncol. 2009 Dec;16(12):3316-22. (PMID: 19707831)
HPB (Oxford). 2016 Aug;18(8):652-63. (PMID: 27485059)
Pancreas. 2008 Jan;36(1):e15-20. (PMID: 18192868)
Saudi J Gastroenterol. 2012 Mar-Apr;18(2):118-21. (PMID: 22421717)
Lancet Oncol. 2013 Oct;14(11):e476-85. (PMID: 24079875)
Int J Cancer. 2015 Oct 15;137(8):1910-20. (PMID: 25895046)
J Am Coll Surg. 2014 Jul;219(1):132-41. (PMID: 24768506)
PLoS Med. 2009 Apr 7;6(4):e1000046. (PMID: 19360088)
J Nucl Med. 2013 Jul;54(7):1101-5. (PMID: 23670900)
Cell Death Differ. 2014 Jan;21(1):15-25. (PMID: 23787994)
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72. (PMID: 20101258)
Front Oncol. 2015 Nov 20;5:254. (PMID: 26636036)
Mol Imaging Biol. 2016 Dec;18(6):807-819. (PMID: 27130234)
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8298-304. (PMID: 26339400)
Transl Oncol. 2011 Apr 01;4(2):71-82. (PMID: 21461170)
J Clin Pathol. 1986 Jun;39(6):610-4. (PMID: 3522636)
J Am Coll Surg. 2006 Sep;203(3):345-52. (PMID: 16931307)
Radiographics. 2012 Jul-Aug;32(4):1133-58; discussion 1158-60. (PMID: 22786999)
Clin Cancer Res. 2015 Aug 15;21(16):3658-66. (PMID: 25904751)
Gut. 2012 Sep;61(9):1315-22. (PMID: 22068166)
Pancreas. 1997 Jul;15(1):35-40. (PMID: 9211490)
J Nucl Med. 2011 Dec;52(12):1839-44. (PMID: 21868625)
Nat Med. 2011 Sep 18;17(10):1315-9. (PMID: 21926976)
Oncotarget. 2015 Jun 10;6(16):14260-73. (PMID: 25895028)
Cancer Res. 2009 Jul 15;69(14 ):5843-50. (PMID: 19549907)
Eur J Surg Oncol. 1991 Aug;17 (4):354-7. (PMID: 1651876)
معلومات مُعتمدة: 323105 International ERC_ European Research Council
فهرسة مساهمة: Keywords: biomarker; molecular imaging; pancreatic cancer
تواريخ الأحداث: Date Created: 20170917 Date Completed: 20170925 Latest Revision: 20220131
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5593604
DOI: 10.18632/oncotarget.18232
PMID: 28915633
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.18232